Mysimba or GLP-1?
Difference in how they work
Mysimba combines bupropion (which influences the reuptake of dopamine and noradrenaline) and naltrexone (an opioid antagonist). Together they can influence appetite and feelings of hunger. GLP-1 medicines work via the GLP-1 receptor and influence satiety and appetite, among other things. So they have different mechanisms of action.
Use and dosage form
| Feature | Mysimba | GLP-1 injections |
|---|---|---|
| Type | Tablet | Injection (subcutaneous) |
| Active substance | Bupropion + naltrexone | E.g. semaglutide or liraglutide |
| Administration | Daily, oral (titration schedule) | Weekly or daily |
| No injection needed | Yes | No |
Mysimba involves a titration schedule in which the number of tablets is built up over several weeks. The doctor determines the dosage.
For whom is Mysimba considered?
Mysimba is registered for weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with weight-related conditions, alongside diet and increased physical activity. For people who do not want an injection, a tablet may be a consideration. Whether it is suitable and safe depends on medical factors and any other medication use.
Difference in effect
The average weight loss differs per medicine and per person. With Mysimba, it is generally advised to reconsider the treatment if there is insufficient effect after several months. Figures on average weight loss are indicative and say nothing about an individual result.
Frequently asked questions
Is Mysimba a GLP-1 medicine?
Is Mysimba an injection?
Can I get Mysimba without a prescription?
Official sources on this topic
Independent, authoritative information from official bodies: